(Q34347249)

1 August 2017

1 reference

title

Pharmacogenetics of warfarin elimination and its clinical implications (English)

1 reference

1 August 2017

1 reference

Takahashi H

1

1 reference

PubMed ID

11523725

1 August 2017

Echizen H

series ordinal

2

1 reference

1 August 2017

1 January 2001

1 reference

Clinical Pharmacokinetics

1 August 2017

1 reference

1 August 2017

40

1 reference

1 August 2017

587-603

1 reference

1 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200140080-00003

1 August 2017

0 references

cites work

Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200140080-00003

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

21 January 2018

1 reference

12 December 2020

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

1 reference

12 December 2020

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

1 reference

12 December 2020

Biochemistry and molecular biology of the human CYP2C subfamily

1 reference

12 December 2020

Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin

1 reference

12 December 2020

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

1 reference

12 December 2020

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

1 reference

12 December 2020

Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California

1 reference

12 December 2020

Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction

1 reference

12 December 2020

Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.

1 reference

12 December 2020

Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations

1 reference

12 December 2020

Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences

1 reference

12 December 2020

Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese

1 reference

12 December 2020

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

1 reference

12 December 2020

Genetic modulation of oral anticoagulation with warfarin

1 reference

12 December 2020

Allelic and functional variability of cytochrome P4502C9.

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluore

1 reference

12 December 2020

Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects

1 reference

12 December 2020

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.

1 reference

12 December 2020

Selective inhibition of warfarin metabolism by diltiazem in humans

1 reference

12 December 2020

Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics

1 reference

12 December 2020

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.

1 reference

12 December 2020

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

1 reference

12 December 2020

Commentary: a physiological approach to hepatic drug clearance

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Studies on the optical enantiomorphs of warfarin in man

1 reference

12 December 2020

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

1 reference

12 December 2020

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

12 December 2020

The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.

1 reference

12 December 2020

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

1 reference

12 December 2020

Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance

1 reference

12 December 2020

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

12 December 2020

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

1 reference

12 December 2020

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes

1 reference

12 December 2020

Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen

1 reference

12 December 2020

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

12 December 2020

Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients.

1 reference

12 December 2020

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.

1 reference

12 December 2020

Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection

1 reference

12 December 2020

Warfarin dose requirement and CYP2C9 polymorphisms

1 reference

12 December 2020

A study of the interaction of omeprazole and warfarin in anticoagulated patients

1 reference

12 December 2020

Human P450 metabolism of warfarin

1 reference

12 December 2020

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

12 December 2020

Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

1 reference

12 December 2020

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

1 reference

12 December 2020

Genetic analysis of CYP2C9 polymorphism in a Japanese population

1 reference

12 December 2020

Glipizide: a review of its pharmacological properties and therapeutic use.

1 reference

12 December 2020

Genetic analysis of the human cytochrome P450 CYP2C9 locus.

1 reference

12 December 2020

The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans

1 reference

12 December 2020

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

12 December 2020

10.2165/00003088-200140080-00003

Identifiers

DOI

1 reference

PubMed ID

11523725

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

11523725